Physician profile
Peter Su
NPI 1184664146
$5,978.49
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $636 · 2021: $882 · 2022: $1,241 · 2023: $1,353 · 2024: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.87 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $611.91 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $588.16 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $544.90 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $412.49 | 2019-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $409.18 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $349.98 | 2019-2023 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $346.06 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Glaxosmithkline, LLC. | $196.16 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.15 | 2019-2023 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $146.81 | 2019-2022 | |
| Abbott Laboratories | $141.56 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $120.01 | 2019-2020 | |
| Eisai INC. | $119.67 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.12 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.62 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.